Navigation Links
PEAK Surgical and Medtronic Announce Global Distribution Agreement for the Ear, Nose, and Throat Market

PALO ALTO, Calif., Oct. 5 /PRNewswire/ -- PEAK Surgical, Inc. and Medtronic, Inc. (NYSE: MDT) today announced an agreement that grants the Surgical Technologies business at Medtronic exclusive rights for global distribution and marketing of the PEAK PlasmaBlade® TnA (Tonsil and Adenoid) tissue dissection device for the ear, nose, and throat (ENT) market.

"PEAK's agreement with Medtronic is a major step toward our goal of capturing significant market share of the sizable global tonsillectomy and adenoidectomy market," said John Tighe, president and chief executive officer of PEAK Surgical. "Medtronic's global reach and extensive ENT product line is a great match for us and we are confident that this agreement, combined with the clinical benefits of the PEAK® Technology, will drive further physician adoption of our devices and technology."

The agreement provides Medtronic with exclusive global distribution rights for the PEAK PlasmaBlade TnA tissue dissection device for the ENT market. Additionally, PEAK will have access to a line of credit that can be used for general working capital purposes.

The PEAK PlasmaBlade TnA is indicated for cutting and coagulation of soft tissue during otolaryngology (ENT) surgery, including removal of the tonsils and adenoids. It is part of the PEAK PlasmaBlade family of disposable, low-temperature surgical cutting and coagulation devices that offer the exacting control of a scalpel and the bleeding control of traditional electrosurgery without the extensive collateral damage to surrounding tissue.

"The PEAK PlasmaBlade TnA complements Medtronic's current products for chronic tonsillitis, otitis media and obstructive sleep apnea," stated Mark Fletcher, president of the ENT division part of the Surgical Technologies business at Medtronic. "We're pleased to offer this technology and expand the treatment solutions we provide to our customers."


Located in Jacksonville, Florida, the ENT division at Medtronic develops and manufactures products designed to treat ENT diseases. As the market leader in ENT, Medtronic is changing the way ENT surgery is performed with innovative, minimally invasive products and techniques that benefit both patients and surgeons. Main products include powered tissue-removal systems and other microendoscopy instruments, nerve monitoring systems, sleep-disordered breathing therapies, image-guided surgery systems, disposable fluid control products, and a Meniere's disease therapy device. Learn more about the ENT business on the web at


Medtronic, Inc. (, headquartered in Minneapolis, is the global leader in medical technology - alleviating pain, restoring health, and extending life for millions of people around the world.


PEAK Surgical, Inc. is a medical device company that has developed the PEAK® Surgery System, a new tissue dissection system based on a proprietary technology that represents an important advance in radiofrequency surgical technologies. The PEAK Surgery System consists of the PEAK PlasmaBlade®, a family of disposable cutting devices that offer the exacting control of a scalpel and the bleeding control of traditional electrosurgery without extensive collateral damage, and the PULSAR® Generator, which supplies pulsed plasma radiofrequency energy to the PlasmaBlade. The PEAK Surgery System is cleared for use in general, plastic and reconstructive, ENT, gynecologic, orthopedic, arthroscopic, spinal and neurological surgical procedures in the United States, and for use in general surgery in the EU. It was launched in the United States in July 2008 and has been used by U.S. surgeons on more than 8,000 patients, including general, gynecologic, and plastic and reconstructive surgeries.

For more information, please visit

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's Annual Report on Form 10-K for the year ended April 24, 2009. Actual results may differ materially from anticipated results.

SOURCE PEAK Surgical, Inc.

SOURCE PEAK Surgical, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Innocoll Announces Dosing of First Patient in US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections in Cardiac Surgery Patients
2. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain
3. Portrait(R) Plasma - A New Non-Surgical Option for one of the Most Requested Aesthetic Treatment - Aging Eyes
4. New Non-Surgical Stem-Cell Procedure to Relieve Chronic Tendon Problems
5. Ceremeds OSTENE(R) Stops Bone Bleeding Without Added Risk of Surgical Infection, New Study Finds
6. Innocoll Announces Dosing of First Patient in Second US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections
7. Anesiva Commences Phase 3 Clinical Trial of Adlea(TM) for Reducing Post-Surgical Pain Following Bunionectomy
8. Anesiva Announces Pivotal Phase 3 Clinical Trial of Adlea(TM) for Reducing Post-Surgical Pain Following Total Knee Replacement
9. PEAK Surgical Announces Positive Results From Preclinical Study of PEAK PlasmaBlade(TM) for Obstetric and Gynecologic Surgery
10. Early Esophageal Cancer and Pre-Cancer Eliminated With Non-Surgical Treatment Combination
11. New Minimally Invasive Surgical Procedure Restores Quality of Life in Patients With Potentially Debilitating Spinal Condition
Post Your Comments:
(Date:6/26/2016)... 2016 One of Australia,s successful ... of a new biotechnology company, Noxopharm Limited [ABN 50 608 966 ... and to list on the ASX. Noxopharm is a ... enter a Phase 1 clinical study later this year. ... of the biggest problems facing cancer patients - the ability of ...
(Date:6/26/2016)... -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) ... Improvements Act of 1976, as amended ("HSR"), with respect ... Nasdaq: CPXX ) expired effective June 24, ... As previously announced on May 31, 2016, Jazz Pharmaceuticals ... which Jazz Pharmaceuticals has commenced a tender offer for ...
(Date:6/26/2016)... , June 27, 2016  VMS Rehab Systems, Inc. ... will take whatever measures required to build a strong ... which is currently listed on the OTC Markets-pink current ... Chairman and CEO, "We are seeing an anomaly in ... understand, not only by the Company, but shareholders and ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... , ... Brent Kasmer, a legally blind and certified personal trainer is helping to develop a ... fitness app plans to fix the two major problems leading the fitness industry today:, ... type program , They don’t eliminate all the reasons people quit their exercise ...
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from the ... AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes Convention Center in ... topics including advance care planning, healthcare costs and patient and family engagement. , ...
(Date:6/25/2016)... , ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library on ... Observer , brings up a new, often overlooked aspect of head lice: the parasite’s ability ... fumigation is not a common occurrence, but a necessary one in the event that lice ...
(Date:6/25/2016)... ... 25, 2016 , ... First Choice Emergency Room , the largest network ... the Medical Director of its new Mesquite-Samuell Farm facility. , “We are pleased ... location,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. ...
(Date:6/25/2016)... City, Oklahoma (PRWEB) , ... June 25, 2016 ... ... helping both athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic ... the Oklahoma City area —Johnson is one of the first doctors to perform ...
Breaking Medicine News(10 mins):